GSK and the University of Oxford will invest up to £50 ($62) million to advance the understanding of how cancer develops, which could inform the future development of vaccines. The agreement establishes the GSK-Oxford Cancer Immuno-Prevention Programme, which unites expertise from four departments across the University and builds on Oxford’s track record in vaccine development. […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!